Translangcomp {float: left; clear: left; difference-top: 15px; * difference-top:-2px; margin-left: 90px}. displaytickersn {display: built-in unit}
HTML> body. displaytickersn {* float: left}
Oxford, England,
September 27, 2011
Circassia Ltd, a company specialty biopharmaceutical focused on allergy, today announced positive phase II clinical results show that its ToleroMune hay fever vaccine significantly improve symptoms of allergic patients compared with placebo. Treatment is well tolerated. In a randomized, double-blind, placebo-controlled second stage of a study conducted in 50 suffer from hay fever in
Quebec, Canada, patients received four doses of one of five different modes of treatment for a 12-week period. Five weeks later, investigators tested patients with skin and eyes the answer to pollen grasses. The results show that treatment to reduce allergic symptoms in the eyes of patients 30% more than placebo. In addition, the therapy improved early and late skin reaction to 54% and 19% above placebo, respectively. ToleroMune T-cell vaccine had a similar safety profile placebo. After these results Circassia proceeded to the final phase II trial of its treatment of hay fever. Double-blind, placebo-controlled study conducted in,
in 280 volunteers, and evaluation ToleroMune T-cell vaccines to improve patients' nasal symptoms and eye responses when exposed to pollen of grass in exposure chambers. "Achieving these results particularly encouraging clinical as hay fever are extremely common allergy that can make a significant impact on the sufferers," said
Circassia CEO. "Many modern therapies to provide short-term relief of symptoms only, while conventional immunotherapy may require the services of a specialist for several years to address the underlying disease. Circassia in the latest results follow previously successful research in a number of different allergies. Our clinical data show that Circassia T-cell vaccines have the potential to revolutionize the treatment of allergies, and these latest results allow us to confidently begin the final phase II trial of our unique treatment of hay fever. "
Circassia developed a number of allergy T-cell vaccines based on its own technology ToleroMune. The company successfully completed a number of studies of phase II with his cat, house dust mites, ragweed and grass allergy treatments. Clinical results show that short treatment regimens T-cell vaccine Circassia can significantly reduce the allergic reaction the patient without adjuvant or other immune stimulants, and show very well. As a result of treatment offer great potential clinical advantages over existing therapies, and have significant market opportunities. Over 150 million people suffer from allergic rhinitis in the U.S., and approximately 15% - 25% of people in buy provigil these countries, which are sensitive to pollen grasses. As a result, the current market allergy treatment worth about
year. Circassia was founded in 2006 by a team of experienced biotechnology scientists and entrepreneurs, headed by former chairman of GlaxoSmithKline, Sir. The company is based in the UK at Oxford Science Park, and where the joint venture Adiga Life Sciences is located. Its ToleroMune technology was developed first, scientists from Imperial College. Successfully passing four rounds of fund-raising, Circassia rose about 93 million (
) and supported by global syndicate of venture capital and institutional investors, including Imperial Innovations and Invesco perpetual. Contacts
